-
Ruxolitinib (sold
under the
brand names Jakafi and
Jakavi among others, and as
Opzelura in
cream form) is a
medication used for the
treatment of intermediate...
-
Administration (FDA)
approved ruxolitinib (Jakafi) as a
treatment for
intermediate or high-risk myelofibrosis.
Ruxolitinib serves as an
inhibitor of JAK...
- three, randomized,
blinded study compares pelabresib and
ruxolitinib with
placebo and
ruxolitinib in
myelofibrosis patients that have not been previously...
- "Topical
Ruxolitinib Evaluation in
Vitiligo Study 1 (TRuE-V1)" at ClinicalTrials.gov
Clinical trial number NCT04057573 for "Topical
Ruxolitinib Evaluation...
- Food and Drug
Administration (FDA)
approved the
first JAK inhibitor,
ruxolitinib, to
treat a skin condition. Some JAK1
inhibitors are
based on a benzimidazole...
- disease. Many
clinical trials are
ongoing involving JAK
inhibitors such as
ruxolitinib and tofacitinib.
Alopecia areata Alopecia totalis "Alopecia universalis...
-
pharmaceutical products,
including Jakafi (
ruxolitinib),
Pemazyre (pemigatinib),
Monjuvi (tafasitamab-cxix),
Opzelura (
Ruxolitinib),
Tabrecta (capmatinib), Olumiant...
-
patients to near-normal life expectancy. Recently, a JAK2 inhibitor,
namely ruxolitinib, has been
approved for use in
primary myelofibrosis.
Trials of these...
- arthritis,
psoriatic arthritis, and
ulcerative colitis; fedratinib, and
ruxolitinib. The
substance is
quickly absorbed from the gut with an
absolute bioavailability...
- agent) or
anagrelide (Agrylin). In J****
kinase 2
positive disorders,
ruxolitinib (Jakafi) can be effective.[citation needed]
Kumar PJ,
Clark ML (2005)...
